In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...

GLP-1RAs have shown considerable effects for weight loss to treat obesity. A recent Phase 3 trial published in Nature Medicine found that tirzepatide led to additional weight loss of over 20% when ...

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

The use of weight-loss jabs may be associated ... Mounjaro – also known as tirzepatide and made by Eli Lilly – for people with a body mass index (BMI) of more than 35 and at least one weight-related ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Global Healthy Living Foundation Says Hims & Hers Health Super Bowl ad omits safety risks and side effects of its weight loss drug.